Willem Fibbe's guest appearances

Willem Fibbe

EHA Hematology Podcast

17th European Haematology Association (EHA) Congress

John Porter

Michael Keating

Jan Geissler

Charles Mullighan

Jing Chen

Mark Frattini

Giora Sharf

OwlTail

Prof Willem Fibbe talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about the use of mesencymal stromal cells and graft-versus-host disease. Mesenchymal stromal cells and stem cells have the ability to modulate and suppress immune responses. These cells are used to suppress a particular disease, graft-versus-host disease, which comes from an allergic response during the transplantation of cells. These cells are harvested from bone marrow and other tissue sources. Normally a specific donor is chosen for each patient. Prof Fibbe also discusses a randomised study that will focus on severe graft-versus-host disease, which also affects the liver, where the patient will be treated with steroids and then two infusions of MSCs, one week apart, if there is no response to steroids.

Prof Willem Fibbe talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about the use of mesencymal stromal cells and graft-versus-host disease. Mesenchymal stromal cells and stem cells have the ability to modulate and suppress immune responses. These cells are used to suppress a particular disease, graft-versus-host disease, which comes from an allergic response during the transplantation of cells. These cells are harvested from bone marrow and other tissue sources. Normally a specific donor is chosen for each patient. Prof Fibbe also discusses a randomised study that will focus on severe graft-versus-host disease, which also affects the liver, where the patient will be treated with steroids and then two infusions of MSCs, one week apart, if there is no response to steroids.

Use of mesenchymal stromal cells against graft-versus-host disease: Prof Willem Fibbe – Lieden University Medical Center